We are live on ! Find out more
CYTK icon

Cytokinetics

382 hedge funds and large institutions have $7.78B invested in Cytokinetics in 2025 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 125 increasing their positions, 103 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

312% more call options, than puts

Call options by funds: $361M | Put options by funds: $87.6M

300% more first-time investments, than exits

New positions opened: 100 | Existing positions closed: 25

38% more capital inflows, than outflows

Capital inflows: $638M | Capital outflows: $463M

33% more funds holding in top 10

Funds holding in top 10: 12 → 16 (+4)

23% more funds holding

Funds holding: 311 → 382 (+71)

21% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 103

3.21% more ownership

Funds ownership: 112.56% → 115.76% (+3.2%)

Holders
382
Holders Change
+71
Holders Change %
+22.83%
% of All Funds
4.99%
Holding in Top 10
16
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+33.33%
% of All Funds
0.21%
New
100
Increased
125
Reduced
103
Closed
25
Calls
$361​M
Puts
$87.6​M
Net Calls
+$273​M
Net Calls Change
+$103​M

CYTK Hedge Fund Activity: Q3 2025 in Review

382 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2025, worth a combined $7.78B — up 71% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 100 funds opened new CYTK positions and 25 closed out — a net gain of 75 holders — while 125 added to existing stakes and 103 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $75.1M. The largest seller was Vestal Point Capital, cutting an estimated $92.7M.

  • 382 institutional investors held Cytokinetics (CYTK) as of Q3 2025, up from 311 in Q2 2025.
  • Funds reported $7.78B of Cytokinetics stock for Q3 2025, up 71% quarter-over-quarter.
  • 100 funds opened new Cytokinetics positions in Q3 2025 and 25 closed out, a net change of +75 holders.
  • The largest Cytokinetics buyer in Q3 2025 was Fidelity Investments, an estimated $75.1M added.
  • The largest Cytokinetics seller in Q3 2025 was Vestal Point Capital, an estimated $92.7M sold.

Based on aggregated 13F filings for Q3 2025.